Centrient Pharmaceuticals is proud to announce it has again received a Gold Sustainability rating from EcoVadis. This affirms Centrient Pharmaceuticals’ commitment to environmental and social sustainability and underlines its position as a sustainable leader in the generics pharmaceutical industry.

The Gold Sustainability rating ranks Centrient Pharmaceuticals in the top 5% of the companies assessed by EcoVadis in the manufacture of basic pharmaceutical products and pharmaceutical preparations industry. The EcoVadis assessment model covers seven management indicators, across 21 sustainability criteria, in four themes: Environment, Labour and Human Rights, Ethics and Sustainable Procurement. Centrient received Advanced standing in all four categories.

'We are very proud that EcoVadis has again awarded Centrient with a Gold rating', says Alba Tiley, Global Sustainability Director at Centrient Pharmaceuticals.' This independent certification demonstrates the progress we make as a company to reach our purpose of improving lives through innovative and sustainable manufacturing of medicines.’ 

Centrient Pharmaceuticals’ products help millions of people to fight life-threatening illnesses and live healthier lives. In 2021, the number of patient treatments facilitated by Centrient amounted to 1,51 billion patient treatments worldwide. Sustainability is at the heart of everything the company does, with priorities set on reducing environmental impact, improving human health and social impact, and combating the further spread of AMR (antimicrobial resistance).

EcoVadis is the world’s most trusted provider of business sustainability ratings, providing detailed assessments of business’ environmental, social and ethical performance. Based on leading standards, such as GRI, UNGC, and ISO 26000, the rating is supervised by an international scientific committee.  EcoVadis Ratings has been tested on over 100,000+ companies across 200+ industries and 175+ countries.